嵌合抗原受体
医学
耐火材料(行星科学)
淋巴瘤
肿瘤科
临床试验
内科学
免疫疗法
癌症
天体生物学
物理
作者
Jérôme Paillassa,Firas Safa
标识
DOI:10.1016/j.lrr.2021.100282
摘要
Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability. Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field.
科研通智能强力驱动
Strongly Powered by AbleSci AI